|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2001-1-9
|
|
pubmed:abstractText |
The salicylate mesalazine is commonly used for the treatment of inflammatory bowel diseases, yet its precise mechanism of action is unknown. Because transcription factor NF-kappaB plays an important role in inflammatory bowel diseases, we investigated the effects of mesalazine therapy on NF-kappaB activation in patients with ulcerative colitis.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0002-9270
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3452-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11151876-Adult,
pubmed-meshheading:11151876-Aged,
pubmed-meshheading:11151876-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:11151876-Biopsy,
pubmed-meshheading:11151876-Colitis, Ulcerative,
pubmed-meshheading:11151876-Double-Blind Method,
pubmed-meshheading:11151876-Female,
pubmed-meshheading:11151876-Humans,
pubmed-meshheading:11151876-Immunohistochemistry,
pubmed-meshheading:11151876-Intestinal Mucosa,
pubmed-meshheading:11151876-Male,
pubmed-meshheading:11151876-Mesalamine,
pubmed-meshheading:11151876-Middle Aged,
pubmed-meshheading:11151876-NF-kappa B,
pubmed-meshheading:11151876-Time Factors
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis.
|
|
pubmed:affiliation |
Department of Internal Medicine B, Medical Clinics, University of Münster, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
